Adli M, Bschor T, Canata B, Döpfmer S, Bauer M. 1998. Lithium in der Behandlung der akuten Depression. Fortschr Neurol Psychiatr 66:435–441.
Akiskal HS, Benazzi F, Perugi G, Rihmer Z. 2005. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 85:245–258.
Akiskal HS, Walker P, Puzantian VR, King D, Rosenthal TL, Dranon M. 1983. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. J Affect Disord 5:115–128.
Altshuler LL, Keck PE, McElroy SL, Suppes T, Brown ES, Denicoff K, et al. 1999. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1:61–65.
Altshuler L, Suppes T, Black D, Nolen WA, Keck PE, Frye MA, et al. 2003a. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 160:1252–1262.
Altshuler LL, Frye MA, Gitlin MJ. 2003b. Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry 53:691–700.
Altshuler LL, Post RM, Black DO, Keck PE, Nolen WA, Frye MA, et al. 2006. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry 67:1551–1560.
Altshuler, LL, Post, RM, Hellemann G, Leverich GS, Nolen WA, Frye MA, et al. 2009. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry, 70:450–457.
American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders . 4th revised ed.
American Psychiatric Press.
Amsterdam J. 1998. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 18:414–417.
Amsterdam JD, Brunswick DJ. 2003. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord 5:388–395.
Amsterdam JD, Garcia-Espana F. 2000. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 59:225–229.
Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, et al. 1998. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 18:435–440.
Anderson J. 2000. On variability of effects for a metaanalysis of rheumatoid arthritis radiographic progression. J Rheumatol 27:540–542.
Andrade C. 2004. Antidepressant-withdrawal mania:a critical review and synthesis of the literature. J Clin Psychiatry 65:987–993.
Angst J. 1985. Switch from depression to mania - a record study over decades between 1920 and 1982. Psychopathology 18:140–154.
Angst J. 2006. Do many patients with depression suffer from bipolar disorder? Can J Psychiatry 51:3–5.
Angst J, Gamma A. 2002. A new bipolar spectrum concept: a brief review. Bipolar disorders 4 (Suppl 1):11–14.
Ayuso-Gutierrez JL. 2005. Depressive subtypes and efficacy of antidepressive pharmacotherapy. World J Biol Psychiatry 6(Suppl 2):31–37.
Baldassano CF, Ghaemi SN, Chang A, Lyman A, Lipari M. 2004. Acute treatment of bipolar depression with adjunctive zonisamide: a retrospective chart review. Bipolar Disord 6:432–434.
Baldessarini RJ, Tondo L, Hennen J. 2003. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 64(Suppl 5):44–52.
Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. 2006. Decreased risk of suicides and atempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord 8:625–639.
Ball JR, Mitchell PB, Corry JC, Skillecorn A, Smith M, Malhi GS. 2006. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psychiatry 67:277–286.
Ballenger JC. 1988. The clinical use of carbamazepine in affective disorder. J Clin Psychiatry 49(Suppl 4):13–19.
Ballenger JC, Post RM. 1980. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137:782–790.
Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Zohar J, et al. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 9:248–312.
Barbey JT, Roose SP. 1998. SSRI safety in overdose. J Clin Psychiatry 59(Suppl 15):42–48.
Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, et al. 2000. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev CD002791.
Baron M, Gershon ES, Rudy V, Jonas WZ, Buchsbaum M. 1975. Lithium carbonate response in depression. Prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. Arch Gen Psychiatry 32:1107–1111.
Bauer M, Hellweg R, Graf KJ, Baumgartner A. 1998. Treatment of refractory depression with high-dose thyroxine. Neuropsy-chopharmacology 18:444–455.
Bauer M, London ED, Rasgon N, Berman SM, Frye MA, Altshuler LL, et al. 2005. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry 10:456–469.
Bech P. 2002. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 106:252–264.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:561–571.
Benazzi F. 2004a. Agitated depression: a valid depression subtype? Prog Neuropsychopharmacol Biol Psychiatry 28:1279–1285.
Benazzi F. 2004b. Mixed states in bipolar II disorder: should full hypomania always be required? Psychiatry Res 127:247–257.
Benazzi F, Akiskal HS. 2006. Psychometric delineation of the most discriminant symptoms of depressive mixed states. Psychiatry Res 141:81–88.
Benazzi F, Akiskal HS. 2008. How best to identify a bipolar-related subtype among major depressive patients without spontaneous hypomania: Superiority of age at onset criterion over recurrence and polarity? J Affect Disord 107:77–88.
Berk M, Malhi GS, Cahill C, Carman AC, Hadzi-Pavlovic D, Hawkins MT, et al. 2007. The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord 9:571–579.
Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I,et al. 2008. N-Acetyl cysteine for depressive symptoms in bipolar disorder- a double-blind randomized placebo-controlled trial. Biol Psychiatry 64:468–475.
Bhagwagar Z, Goodwin GM. 2002. The role of lithium in the treatment of bipolar depression. Clin Neurosci Res 2: 222–227.
Boerlin HL, Gitlin MJ, Zoellner LA, Hammen CL. 1998. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry 59:374–379.
Bond DJ, Noronha MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. 2008. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: A systematic review and meta-analysis. J Clin Psychiatry 69:1589–1601.
Bottlender R, Rudolf D, Strauβ A, Möller H-J. 1998. Antidepressant-associated maniform states in acute treatment of patients with bipolar I depression. Eur Arch Psychiatry Clin Neurosci 248:296–300.
Bowden CL, Singh V. 2005. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand Suppl13–20.
Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. 2000. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57:481–489.
Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. 2004. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 27:173–184.
Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. 2009. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166:42–49.
Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH,Degenhardt E, et al. 2009. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 12(6):773–782.
Brown EB, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen M, Williamson DJ. 2006. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 67:1025–1033.
Bunney WE, Murphy DL, Goodwin FK, Borge GF. 1972. The ‘switch process’ in manic-depressive illness. I. A systematic study of sequential behavioral changes. Arch Gen Psychiatry 27:295–302.
Calabrese JR, Rapport DJ, Shelton MD, Kimmel SE. 1998. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology 38:185–191.
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd G, for the Lamictal 602 Study Group. 1999a. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 60:79–88.
Calabrese JR, Rapport DJ, Kimmel SE, Shelton MD. 1999b. Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur Neuropsychopharmacol 9(Suppl 4):109–112.
Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA,Weisler RH, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. Am J Psychiatry 162:1351–1360.
Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR,Ascher JA, et al. 2008. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 10:323–333.
Carlson GA, Finch SJ, Fochtmann LJ, Ye Q, Wang Q, Naz B, Bromet EJ. 2007. Antidepressant-associated switches from depression to mania in severe bipolar disorder. Bipolar Disord 9:851–859.
Carta MG, Hardoy MC, Hardoy MJ, Grunze H, Carpiniello B. 2003. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord 75:83–91.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. 2009. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758.
Cohn JB, Collins G, Ashbrook E, Wernicke JF. 1989. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 4:313–322.
Colom F, Vieta E. 2004. A perspective on the use of psychoeducation, cognitive-behavioral therapy and interpersonal therapy for bipolar patients. Bipolar Disord 6:480–486.
Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A,Gasto C. 2000. Clinical factors associated with treatment non-compliance in euthymic bipolar patients. J Clin Psychiatry 61:549–555.
Colom F, Vieta E, Daban C, Pacchiarotti I, Sanchez-Moreno J. 2006. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 93:13–17.
Colombo C, Benedetti F, Barbini B, Campori E, Smeraldi E. 1999. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res 86:267–270.
Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF. 2006. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine mono-therapy in the treatment of bipolar depression. J Clin Psychiatry 67:798–806.
Crossley NA, Bauer M. 2007. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935–940.
Daban C, Martinez-Aran A, Cruz N, Vieta E. 2008. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord 110:1–15.
Davis LL, Bartolucci A, Petty F. 2005. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 85:259–266.
Dilsaver SC, Swann SC, Chen YW, Shoaib A, Joe B, Krajewski KJ, et al. 1996. Treatment of bipolar depression with carbamazepine: results of an open study. Biol Psychiatry 40:935–937.
Dunner DL, Dunbar GC. 1992. Optimal dose regimen for paroxetine. J Clin Psychiatry 53(Suppl):21–26.
Evins EA, Demopulos C, Yovel I, Culhane M, Ogutha J,Grandin LD, et al. 2006. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 8:168–174.
FDA Public Health Advisory. 2004. Suicidality in children and adolescents being treated with antidepressant medications. Electronic Citation US Food and Drug Administration .
Fernandes BS, Gama CS, Kauer-Sant'Anna M, Lobato MI,Belmonte-de-Abreu P, & Kapczinski F. 2009. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis. J Psychiatr Res 43:1200–1204.
Fetter JC, Askland KD. 2005. Antidepressants for bipolar depression. Am J Psychiatry 162:1546–1548.
Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. 2008.Treatment of bipolar depression: An update. J Affect Disord 109:21–34.
Frangou S, Lewis M, McCrone P. 2006. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 188:46–50.
Frank E. 2007. Interpersonal and social rhythm therapy: a means of improving depression and preventing relapse in bipolar disorder. J Clin Psychol 63:463–473.
Frey R, Schreinzer D, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S. 2000. Suicide by antidepressant intoxication at autopsy in Vienna between 1991–1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 10:133–142.
Frye M, Ketter T, Kimbrell TA, Dunn R, Speer A, Osuch E, et al. 2000. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20:607–614.
Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE, Walden J,et al. 2007. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 164:1242–1249.
Frye MA, Helleman G, McElroy SL, Altshuler LL, Black DO,Keck PE, et al. 2009. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 166:164–172.
Gajwani P, Forsthoff A, Muzina D, Amann B, Gao K, Elhaj O,et al. 2005. Antiepileptic drugs in mood-disordered patients. Epilepsia 46(Suppl 4):38–44.
Gao K, Ganocy SJ, Gajwani P, Mühlbauer HD, Kemp DE, Calabrese JR. 2008a. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 69:302–309.
Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. 2008b. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 28:203–209.
Geddes JR, Calabrese JR, Goodwin GM. 2009. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4–9.
Ghaemi SN, Goodwin FK. 2005. Antidepressants for bipolar depression. Am J Psychiatry 162:1545–1546.
Ghaemi SN, Ko JK, Goodwin FK. 2002. “Cade's Disease” and beyond: Misdiagnosis, antidepressant use, and proposed definition for bipolar spectrum disorder. Can J Psychiatry 47: 125–134.
Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, Sachs G. 2006a. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv 57:660–665.
Ghaemi SN, Zablotsky B, Filkowski MM, Dunn RT, Pardo TB, Isenstein E, Baldassano CF. 2006b. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 26:385–388.
Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, et al. 2007. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 68:1840–1844.
Ghaemi NS, Shirzadi AA, Filkowski M. 2008a. Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder. Medscape J Med 10:211.
Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. 2008b. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 118: 347–356.
Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ. 2007. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356–1363.
Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. 2004. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161:1537–1547.
Goldberg JF, Burdick KE, Endick CJ. 2004. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 161:564–566.
Goldberg JF, Perlis RH, Ghaemi SN, Calabrese JR, Bowden CL,Wisniewski S, et al. 2007. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 164:1348–1355.
Goldberg JF, Brooks JO III, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, et al. 2009a. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 70:155–162.
Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB, Calabrese JR, et al. 2009b. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry 166:173–181.
Gonzalez-Pinto A, Gonzalez C, Enjuto S, Fernandez dC, Lopez P, Palomo J, et al. 2004. Psychoeducation and cognitive-behavioral therapy in bipolar disorder: an update. Acta Psychiatr Scand 109:83–90.
Goodnick PJ, Rush AJ, George MS, Marangell LB, Sackeim HA. 2001. Vagus nerve stimulation in depression. Expert Opin Pharmacother 2:1061–1063.
Goodwin FK, Jamison KR. 2007. Manic-depressive illness . 2nd ed.
Oxford University Press.
Goodwin FK, Murphy DL, Dunner DL, Bunney WE. 1972.Lithium response in unipolar versus bipolar depression. Am J Psychiatry 129:44–47.
Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, et al. 2004. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65:432–441.
Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C,Mitchell PB, et al. 2008. ECNP consensus meeting. Bipolar Depression. Nice, March 2007. Eur Neuropsychopharmacol 18:535–549.
Grunze H. 2003. Lithium in the acute treatment of bipolar disorders-a stocktaking. Eur Arch Psychiatry Clin Neurosci 253:115–119.
Grunze H. 2006. Carbamazepine, other anticonvulsants and augmenting agents. In: Akiskal HS, Tohen M, editors. Bipolar psychopharmacotherapy: Caring for the patient.
John Wiley & Sons. p 63–84.
Grunze H, Walden J. 2002. Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder. J Affect Disord 72(Suppl 1):15–21.
Grunze H, Kasper S, Goodwin G, Bowden CL, Baldwin D, Licht RW, Vieta E, Möller H-J, WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. 2002b. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders. Part I: Treatment of Bipolar Depression. World J Biol Psychiatry 3: 115–124.
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. 2009. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. World J Biol Psychiatry 10:85–116.
Grunze HC. 2008a. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr 13:790–795.
Grunze HC. 2008b, Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr 13:790–795.
Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, et al. 2003. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28:1374–1382.
Hallam KT, Smith DI, Berk M. 2009. Differences between subjective and objective assessments of the utility of Electrocon-vulsive therapy in patients with bipolar and unipolar depression. J Affect Disord 112:212–218.
Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296.
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. 2006. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185–194.
Himmelhoch JM, Fuchs CZ, Symons BJ. 1982. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 170:628–634.
Himmelhoch JM, Thase ME, Mallinger AG, Houck P. 1991.Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148:910–916.
Hirschfeld RM, Fochtmann LJ, McIntyre JS. 2005. Antidepressants for bipolar depression. Am J Psychiatry 162:1546–1547.
Hurley SC. 2002. Lamotrigine update and its use in mood disorders. Ann Pharmacother 36:860–873.
Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB,Roth BL. 2008. N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsy-chopharmacology 33:2303–2312.
Jon DI, Bahk WM, Yoon BH, Shin YC, Cho HS, Lee E, et al. 2008. Revised Korean medication algorithm for bipolar disorder. World J Biol Psychiatry 10:1–10.
Jones S. 2004. Psychotherapy of bipolar disorder: a review. J Affect Disord 80:101–114.
Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. 2002. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59:530–537.
Judd LL, Schettler PJ, Akiskal HS, Coryell W, Leon AC, Maser JD, Solomon DA. 2008. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry 65: 386–394.
Kantrowitz JT, Citrome L. 2008. Olanzapine: review of safety 2008. Expert Opin Drug Saf 7:761–769.
Kasper S, Calabrese JR, Johnson G, Tajima O, Vieta E, Viguera AC, et al. 2008. International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression. J Clin Psychiatry 69:1632–1646.
Keck PE, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, et al. 2005. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry 66:611–616.
Keck PE, Mintz J, McElroy SL, Freeman MP, Suppes T,Frye MA, et al. 2006. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60:1020–1022.
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ,Johnson BT. 2008. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45.
Kupfer DJ, Frank E, Grochocinski VJ, Luther JF, Houck PR,Swartz HA, Mallinger AG. 2000. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr 12:3–114.
Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. 2007. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 9:531–535.
Lader MH. 1996. Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry 57(Suppl 2):39–44.
Lambert PA. 1984. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okuma T, Müller AA, editors. Anticonvulsants in affective disorders.
Amsterdam, Oxford, Princeton:
Elsevier Science Publishers. p 33–44.
Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL,Keck PE, J, et al. 2006. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 163:232–239.
Leverich GS, Post RM, Keck PE, Altshuler LL, Frye MA, Kupka RW, et al. 2007. The poor prognosis of childhood-onset bipolar disorder. J Pediatr 150:485–490.
Lewis JL, Winokur G. 1982. The induction of mania. A natural history study with controls. Arch Gen Psychiatry 39:303–306.
Lexchin J, Light DW. 2006. Commercial influence and the content of medical journals. Br Med J 332:1444–1447.
Lexchin J, Bero LA, Djulbegovic B, Clark O. 2003. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br Med J 326:1167–1170.
Licht RW, Vestergaard P, Kessing LV, Larsen JK, Thomsen PH. 2003. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl1–22.
Licht RW, Qvitzau S, Allerup P, Bech P. 2005. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 111: 144–149.
Licht RW, Gijsman H, Nolen WA, Angst J. 2008. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 118:337–346.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. 2005. Effectiveness of antipsychoticdrugs in patients with chronic schizophrenia. New Engl J Med 353:1209–1223.
Macedo-Soares MB, Moreno RA, Rigonatti SP, Lafer B. 2005. Efficacy of electroconvulsive therapy in treatment-resistant bipolar disorder: a case series. J ECT 21:31–34.
Maj M, Pirozzi R, Magliano L, Bartoli L. 2003. Agitated depression in bipolar I disorder: prevalence, phenomenology, and outcome. Am J Psychiatry 160:2134–2140.
Marangell LB, Dennehy EB, Miyahara S, Wisniewski SR, Bauer MS, Rapaport MH, et al. 2009. The functional impact of sub-syndromal depressive symptoms in bipolar disorder: Data from STEP-BD. J Affect Disord 114:58–67.
Masan PS. 2004. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 16:3–13.
Matkowski K, Rybakowski J. 1992. Karbamazepina w leczeniu chorob depresyjnych. Psychiatr Pol 26:251–258.
McAllister-Williams RH. 2008. Do antidepressants work? A commentary on “Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration” by Kirsch et al. Evid Based Ment Health 11:66–68.
McCormack PL, Wiseman LR. 2004. Olanzapine: a review of its use in the management of bipolar I disorder. Drugs 64: 2709–2726.
McElroy SL, Suppes T, Keck PE, Black D, Frye MA, Altshuler LL, et al. 2005. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 66:617–624.
McElroy SL, Young AH, Carlsson A, Olausson B, Nordenhem A,Paulsson B, Brecher M. 2008. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and paroxetine in adults with bipolar deprsssion (EMBOLDEN II). Bipolar Disord 10(Suppl 1):59.
McIntyre RS, Mancini DA, Parikh S, Kennedy SH. 2001. Lithium revisited. Can J Psychiatry 46:322–327.
McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. 2002. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 4:207–213.
Meador KJ, Baker GA, Browning N, Clayton-Smith J, CombsCantrell DT, Cohen M, et al. 2009. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New Engl J Med 360:1597–1605.
Mendlewicz J, Youdim MB. 1980. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J Affect Disord 2:137–146.
Miklowitz DJ, Otto MW. 2007. Psychosocial interventions for bipolar disorder: a review of literature and introduction of the systematic treatment enhancement program. Psychopharmacol Bull 40:116–131.
Miklowitz DJ, Frank E, George EL. 1996. New psychosocial treatments for the outpatient management of bipolar disorder. Psychopharmacol Bull 32:613–621.
Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Kogan JN, Sachs GS, Thase ME, Calabrese JR, Marangell LB, Ostacher MJ, Patel J, Thomas MR, Araga M, Gonzalez JM, Wisniewski SR. 2007. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry 164:1340–1347.
Mitchell PB, Malhi GS. 2004. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord 6:530–539.
Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. 2008. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 10:144–152.
Möller HJ. 2008. Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455.
Möller HJ. 2009. Standardised rating scales in Psychiatry: Methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 10:6–26.
Möller HJ, Berzewski H, Eckmann F, Gonzalves N, Kissling W, Knorr W, et al. 1993. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 26:75–78.
Möller HJ, Bottlender R, Grunze H, Strauss A, Wittmann J. 2001. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Affect Disord 67:141–146.
Möller HJ, Grunze H, Broich K. 2006. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci 256:1–16.
Moller HJ, Baldwin DS, Goodwin G, Kasper S, Okasha A, Stein DJ, Tandon R, Versiani M. 2008. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 258 Suppl3:3–23.
Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.
Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lepine JP, Moller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME. 2007. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323–329.
Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. 2006. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77:193–198.
Müller-Oerlinghausen B, Ahrens B, Felber W. 2006. The suicide-preventive and mortality reducing effect of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds) Lithium in Neuropsychiatry: The Comprehensive Guide.
Oxfordshire, UK: pp 179–192.
Muzina DJ, Ganocy SJ, Khalife S, and Gao K. A double-blind, placebo-controlled study of divalproex extended-release in newly-diagnosed mood stabilizer naive patients with acute bipolar depression.
Presented at the 48th Annual New Clinical Drug Evaluation Unit Meeting (NCDEU), May 2008,
2008. Ref Type: Conference Proceeding.
Nahas Z, Kozel FA, Li X, Anderson B, George MS. 2003. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disord 5:40–47.
National Collaborating Centre for Mental Health (2006) Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. CG38: NICE Guideline. Electronic Citation National Institute for Health and Clinical Excellence .
Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD. 2001. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 158:906–912.
Neumann J, Seidel K, Wunderlich H-P. 1984. Comparative studies of the effect of carbamazepine and trimipramine in depression. In: Emrich HM, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders.
Amsterdam: pp 160–166.
Ng F, Dodd S, Berk M. 2007. The effects of physical activity in the acute treatment of bipolar disorder: a pilot study. J Affect Disord 101:259–262.
Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS. 2006. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 163:210–216.
Nolen WA, Kupka RW, Hellemann G, Frye MA, Altshuler LL, Leverich GS, Suppes T, Keck PE, Jr., McElroy S, Grunze H, Mintz J, Post RM. 2007. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 115: 360–365.
Nolen WA, Kupka RW, Schulte PFJ, Knoppert-van der Klein EAM, Honig A, Reichart CG, Goossens PJJ, Daemen P, Ravelli DP. 2008. Richtlijn bipolaire stoornissen . 2 ed.
De Tijdstrom uitgerverij BV,
O'Donovan C, Gamham JC, Hajek T, Alda M. 2008. Antidepressant monotherapy in pre-bipolar depression: Predictive value and inherent risk. J Affect Disord 107:293–298.
Parker G, Tully L, Olley A, Hadzi-Pavlovic D. 2006. SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J Affect Disord 92:205–214.
Peretti S, Judge R, Hindmarch I. 2000. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl403:17–25.
Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. 2005. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162:1957–1960.
Perlis RH, Brown E, Baker RW, Nierenberg AA. 2006. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am J Psychiatry 163:225–231.
Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, Akiskal HS. 2002. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol 22:584–591.
Pichot P. 1995. The birth of the bipolar disorder. Eur Psychiatry 1–10.
Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Keck PE, et al. 2003. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 5:310–319.
Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA,Kupka RW, et al. 2006. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 189:124–131.
Quitkin FM, Kane J, Rifkin A, Ramos-Lorenzi JR, Nayak DV.1981. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Arch Gen Psychiatry 38:902–907.
Riemann D, Voderholzer U, Berger M. 2002. Sleep and sleep-wake manipulations in bipolar depression. Neuropsychobiology 45(Suppl 1):13–19.
Rihmer Z. 2005. Prediction and prevention of suicide in bipolar disorders. Clin Neuropsychiatry 2:48–54.
Rihmer Z, Akiskal H. 2006. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 94:3–13.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. 2004. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust NZ J Psychiatry 38: 280–305.
Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. 1986. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 18:65–87.
Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, et al. 2000. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 47:276–286.
Sachs G, Collins MA, Altshuler L, Ketter T, Suppes T, Rasgon N, et al. 2002. Divalproex sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus & Proceedings Summary .
Sachs G, Lombardo I, Yang R, Kremer C, Pappadopulos E. 2009. Learnings from the ziprasidone bipolar depression program.
ISCTM 5th Annual Meeting,
Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF. 1994. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 55: 391–393.
Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, et al. 2003. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53:1028–1042.
Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. 2007. Effectiveness of adjunctive antidepressant treatment for bipolar depression. New Engl J Med 356:1711–1722.
Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, et al. 2001. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. J Am Med Assoc 285:1299–1307.
Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W, et al. 2007. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol 10(Suppl 1):1–207.
Schaffer A, Zuker P, Levitt A. 2006. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 96: 95–99.
Severus WE, Kleindienst N, Evoniuk G, Bowden C, Moller HJ, Bohus M, et al. 2009. Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study. J Affect Disord 115: 466–470.
Silverstone T. 2001. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand 104:104–109.
Silverstone PH, Silverstone T. 2004. A review of acute treatments for bipolar depression. Int Clin Psychopharmacol 19:113–124.
Simon GE, Savarino J, Operskalski B, Wang PS. 2006. Suicide risk during antidepressant treatment. American Journal of Psychiatry 163:41–47.
Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, et al. 2004. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol 24:512–520.
Small JG. 1990. Anticonvulsants in affective disorders. Psychopharmacol Bull 26:25–36.
Sokolski KN, Denson TF. 2003. Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Prog Neuropsychopharmacol Biol Psychiatry 27:863–866.
Spina E, Pisani F, Perucca E. 1996. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 31:198–214.
Suppes, T. 2008. Effectiveness of the new extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (trial D144CC00002).
Presented at the Eighth International Review of Bipolar Disorder Conference,
14–16 April, 2008.
Suppes T, Kelly DI, Keck PE, McElroy SL, Altshuler LL, Mintz J, et al. 2007. Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network. Int Clin Psychopharmacol 22:376–381.
Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. 2008. Quetiapine for the treatment of bipolar II depression: Analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 9:198–211.
Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR. 2006. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600–609.
Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. 2008. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 28:13–20.
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. 2003. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079–1088.
Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, et al. 2009. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 11:453–473.
Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, et al. 2007. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 68:1472–1479.
Valenti M, Benabarre A, Bernardo M, Garcia-Amador M, Amann B, Vieta E. 2007. La terapia electroconsultiva en el tratamiento de la depresion bipolar. Actas Esp Psiquiatr 35:199–207.
van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, et al. 2009. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 70:223–231.
Vieta E. 2005. The package of care for patients with bipolar depression. J Clin Psychiatry 66(Suppl 5):34–39.
Vieta E. 2008. Antidepressants in bipolar depression. Acta Psychiatr Scand 118:335–336.
Vieta E, Suppes T. 2008. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord 10:163–178.
Vieta E, Martinez-Aran A, Nieto E, Colom F, Reinares M, Benabarre A, Gasto C. 2000. Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 15:433–437.
Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M. 2002. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 63:508–512.
Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. 2007. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 9:413–425.
Visser HM, Van der Mast RC. 2005. Bipolar disorder, antidepressants and induction of hypomania or mania. A systematic review. World J Biol Psychiatry 6:231–241.
Wehr TA, Goodwin FK. 1987. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 144:1403–1411.
Weissman MM. 1997. Interpersonal psychotherapy: current status. Keio J Med 46:105–110.
Wilson MS, Findling RL. 2007. Zonisamide for bipolar depression. Expert Opin Pharmacother 8:111–113.
Winokur G, Coryell W, Endicott J, Akiskal H. 1993. Further distinctions between manic-depressive illness (bipolar disorder) and primary depressive disorder (unipolar depression). Am J Psychiatry 150:1176–1181.
Winsberg ME, DeGolia SG, Strong CM, Ketter TA. 2001. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 67:207–212.
Woo YS, Chae JH, Jun TY, Kim KS, Bahk WM. 2008. The bipolar diathesis of treatment-resistant major depressive disorder. Int J Psychiaty Clin Practice 12:142–146.
World Health Organization. 1992. The ICD-10 Classification of Mental and behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines .
Wu JC, Kelsoe JR, Schachat C, Bunney BG, Demodena A, Golshan S, et al. 2009. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 66:298–301.
Xia G, Gajwani P, Muzina DJ, Kemp DE, Gao K, Ganocy SJ, Calabrese JR. 2008. Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation. Int J Neuropsychopharmacol 11: 119–130.
Yasmin S, Carpenter LL, Leon Z, Siniscalchi JM, Price LH. 2001. Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review. J Affect Disord 63:243–247.
Yatham LN, Srisurapanont M, Zis AP, Kusumakar V. 1997. Comparative studies of the biological distinction between unipolar and bipolar depressions. Life Sci 61:1445–1455.
Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, Macqueen G, McIntyre RS, et al. 2006. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 8:721–739.
Young AH, Newham JI. 2006. Lithium in maintenance therapy for bipolar disorder. J Psychopharmacol 20:17–22.
Young LT, Robb JC, Patelis S, I, MacDonald C, Joffe RT. 1997. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 42:851–853.
Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. 2000. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157:124–126.
Young AH, Carlsson A, Olausson B, Paulsson B, Brecher M. 2008. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and lithium in adults with bipolar depression (EmboldenI). Bipolar Disord 10(Suppl 1):451.
Zarate CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. 2004. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 56:54–60.
Zaretsky AE, Segal ZV, Gemar M. 1999. Cognitive therapy for bipolar depression: a pilot study. Can J Psychiatry 44: 491–494.
Zhang ZJ, Kang WH, Tan QR, Li Q, Gao CG, Zhang FG, et al. 2007. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. J Psychiatr Res 41:360–369.
Zornberg GL, Pope HG. 1993. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 13:397–408.